Passeo™-18 Lux™

Peripheral Drug-Coated Balloon Catheter

Clinically proven results in challenging patient groups.

Safe and effective in the treatment of lower limb arteries[1,2]

Clinically proven

Excellent results despite a complex population at baseline[2]

For challenging patient groups

Reduction of drug loss with SafeGuard™ Insertion Aid[3]

Effective drug delivery

Teleflex™

Empowering the future of healthcare

Passeo™-18 Lux™ DCB

Clinically proven for challenging patient groups with effective drug delivery.[1–4]

For challenging patient groups

Safety and efficacy clinically proven at 24 months across challenging subgroups in BIOLUX P-III all-comers registry.

BIOLUX P-III Subgroup	RC 5+6 Enrollment	Freedom from MAE◊,ϕ (%)	Freedom from cd-TLR◊ (%)
FEMPOP[3]	28.9%	84.9	88.9
CLI[5]	68.6%	80.6	87.9
BTK[6]	63.6%	79.0	90.9
DM[7]	40.9%	80.0	87.1
ISR[3]	21.2%	72.5	78.4

24 months



FEMPOP: Femoropopliteal; CLI: Critical Limb Ischemia; BTK: Below The Knee; DM: Diabetes Mellitus; ISR: In Stent Restenosis; RC: Rutherford Classification; MAE: Major Adverse Events; cd-TLR: clinically driven Target Lesion Revascularization

◊Kaplan-Meier estimates; ϕDefined as composite of device – and procedure-related mortality through 30 days, and major target limb amputation and clinically driven target lesion revascularization.

1. Scheinert D. Paclitaxel Releasing Balloon in femoropopliteal lesions using BTHC excipient: 12-month results from the BIOLUX P-I randomized trial. JEVT, 2015; 22(1): 14-21; 2. Zeller et al. Paclitaxel-Coated Balloon in Infrapopliteal arteries 12-month results from the BIOLUX P-II randomized trial. J Am Coll Cardiol Intv. 2015; 8: 1614-22; 3. Tepe G. Paclitaxel-Coated Balloon Angioplasty for the Treatment of Infrainguinal Arteries: 24-Month Outcomes in the Full Cohort of BIOLUX P-III Global Registry. Cardiovasc Intervent Radiol.2021;44:207-217; 4. Data on file; 5. Brodmann B et al. Real-World Experience With a Paclitaxel-Coated Balloon in Critical Limb Ischemia 24-Month Subgroup Outcomes of BIOLUX P-III. JACC Cardiovasc Interv. 2020;13:2289-2299; 6. Tepe G et al. BIOLUX P-III Passeo-18 Lux All-Comers Registry: 24-Month Results in Below-the-Knee Arteries. Cardiovasc Intervent Radiol. 2021;44:10-18; 7. Mwipatayi P, Barry I, Brodmann M, et al. Twenty-Four-Month Outcomes of Drug-Coated Balloon in Diabetic Patients in the BIOLUX P-III Registry: A Subgroup Analysis. Annals of Vascular Surgery (2021); https://doi.org/10.1016/j.avsg.2021.02.050.

Teleflex™
Empowering the future of healthcare